Target | Sensitivity (%) | Specificity (%) | False positive in |
Bladder tumor antigen | 50 to 90 | 90 | Urinary tract infection, hematuria, calculi, BPH, prior intravesical treatment |
NMP 22 | 42 to 100 | 70 to 91 | Inflammation |
NMP 52 | 97 | 94 | |
BLCA-4 | 89 to 96 | 95 to 100 | |
BLCA-1 | 80 | 87 | |
Survivin | 64 to 100 | 93 to 100 | |
CK 8 and CK 18 | 35 to 79 | 68 | |
CK 19 | 43 to 96 | 70 | Urinary tract infection, calculi, post-BCG |
FDP | 70 | 68 to 86 | |
Hyaluronic acid, hyaluronidase | 82 to 100 | 81 to 90 | |
mRNA markers |
Cxbladder* | 74 to 95 | 45 to 81 | |
Xpert Bladder Cancer Monitor¶ | 46 to 84 | 77 to 95 | |